ReviewExpert opinion on biological therapy2008
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.
Review in Expert opinion on biological therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials.PLoS pathogens · 2021Article
- The immunological impact of adenovirus early genes on vaccine-induced responses in mice and nonhuman primates.Journal of virology · 2021Article
- An SAMT-247 Microbicide Provides Potent Protection against Intravaginal Simian Immunodeficiency Virus Infection of Rhesus Macaques, whereas an Added Vaccine Component Elicits Mixed Outcomes.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- A Mucosal Adenovirus Prime/Systemic Envelope Boost Vaccine Regimen Elicits Responses in Cervicovaginal and Alveolar Macrophages of Rhesus Macaques Associated With Delayed SIV Acquisition and B Cell Help.Frontiers in immunology · 2020Article
- Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses againstJournal of immunology (Baltimore, Md. : 1950) · 2019Article
- Early T Follicular Helper Cell Responses and Germinal Center Reactions Are Associated with Viremia Control in Immunized Rhesus Macaques.Journal of virology · 2019Article
- Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission.Current immunology reviews · 2019Article
- Replicating Adenovirus-SIV Immunization of Rhesus Macaques Induces Mucosal Dendritic Cell Activation and Function Leading to Rectal Immune Responses.Frontiers in immunology · 2019Article
- Article
- Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques.Clinical immunology (Orlando, Fla.) · 2014Article
- Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.Clinical immunology (Orlando, Fla.) · 2014Article
- Article
- The influence of delivery vectors on HIV vaccine efficacy.Frontiers in microbiology · 2014Review
- Development of replication-competent viral vectors for HIV vaccine delivery.Current opinion in HIV and AIDS · 2013Review
- Article
- Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.Clinical and vaccine immunology : CVI · 2012Article
- Article
- Controlling the HIV/AIDS epidemic: current status and global challenges.Frontiers in immunology · 2012Article
- Article
- DNA vaccines for targeting bacterial infections.Expert review of vaccines · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundIn recent years the HIV vaccine field introduced a number of promising vaccine candidates into human clinical trials.
objectiveTo briefly discuss the advances made in vaccine development and HIV pathogenesis and give an overview of the body of work our lab has generated in multiple animal models on replication-competent Adenovirus recombinant vaccines.
methodsEmphasis is placed on comparative examination of vaccine components, routes of immunization and challenge models using replicating Adenovirus vectors. RESULTS/
conclusionThe findings make the case that replicating Adenovirus vectors are superior in priming multiple arms of the immune system, and in conjunction with protein boosting, have resulted in dramatic protective efficacy leading to their advancement to Phase I trials. Implications of the recent halting of the Merck Ad5-HIV Phase IIb clinical trial of our vaccine approach and other vectored vaccines are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.